NEW YORK – (GenomeWeb News) – Lab21 said today that it will offer five of DeCode Genetics’ tests in the UK and in Ireland, and it will have the rights to offer new tests that are not yet on the market.
The agreement allows the Cambridge, UK-based Lab21 to offer DeCode’s tests for type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer, and glaucoma, as well as an upcoming test for the risk of estrogen-positive breast cancer and “a pipeline” of other tests DeCode has in development.
Lab21 also offers tests from Myriad Genetics and PGxHealth, including tests for various cancers and for cardiovascular disease. The company said that all the DeCode tests it has agreed to market have “full regulatory approval.”
Financial terms of the agreement were not released.